new drug update 2016 - cdn.ymaws.com · • new drug update 2016 is accredited for 1.5 contact...
TRANSCRIPT
![Page 1: NEW DRUG UPDATE 2016 - cdn.ymaws.com · • New Drug Update 2016 is accredited for 1.5 contact hours – Pharmacists ACPE 0154-0000-16-010-L01-P – Technicians ACPE 0154-0000-16-010-L01-T](https://reader033.vdocument.in/reader033/viewer/2022060600/60543e4917da3737fa6a5a6a/html5/thumbnails/1.jpg)
NEWDRUGUPDATE2016LaurajoRyan,PharmD,MSc,BCPS
BrysonDuhon,PharmD,BCPSClinicalAssistantProfessor
![Page 2: NEW DRUG UPDATE 2016 - cdn.ymaws.com · • New Drug Update 2016 is accredited for 1.5 contact hours – Pharmacists ACPE 0154-0000-16-010-L01-P – Technicians ACPE 0154-0000-16-010-L01-T](https://reader033.vdocument.in/reader033/viewer/2022060600/60543e4917da3737fa6a5a6a/html5/thumbnails/2.jpg)
AccreditaIon• NewDrugUpdate2016isaccreditedfor1.5contacthours– Pharmacists ACPE0154-0000-16-010-L01-P– Technicians ACPE0154-0000-16-010-L01-T– BrysonDuhon&LaurajoRyanhavenotdisclosedanyfinancialorconflictsofinterestinrelaIontothisprogram
![Page 3: NEW DRUG UPDATE 2016 - cdn.ymaws.com · • New Drug Update 2016 is accredited for 1.5 contact hours – Pharmacists ACPE 0154-0000-16-010-L01-P – Technicians ACPE 0154-0000-16-010-L01-T](https://reader033.vdocument.in/reader033/viewer/2022060600/60543e4917da3737fa6a5a6a/html5/thumbnails/3.jpg)
PresentaIonObjecIves1. Discussthebasicpharmacologyofthenew
drugspresentedandhowthepharmacologicacIonsrelatetoboththerapeuIcandadverseeffects.
2. DiscussclinicallysignificantadverseeffectsanddruginteracIons,andtheappropriatedosingandmonitoringofthenewdrugspresented.
3. DiscussthetherapeuIcroleofthenewdrugspresentedascomparedtoagentsalreadymarketed.
![Page 4: NEW DRUG UPDATE 2016 - cdn.ymaws.com · • New Drug Update 2016 is accredited for 1.5 contact hours – Pharmacists ACPE 0154-0000-16-010-L01-P – Technicians ACPE 0154-0000-16-010-L01-T](https://reader033.vdocument.in/reader033/viewer/2022060600/60543e4917da3737fa6a5a6a/html5/thumbnails/4.jpg)
NotableDrugPatentExpiraIonsin2016• Crestor–$6.4billionannualrevenue• Benicar–$2.6billionannualrevenue• ZeIa–$2.6billionannualrevenue• Cubicin–$1.5billionannualrevenue• SeroquelXR–$1.2billionannualrevenue• AciphexSprinkle–$1.1billionannualrevenue• Norvir–$1.0billionannualrevenue• Kaletra–$1.0billionannualrevenue• Epzicom–$1.0billionrevenue
hap://medcitynews.com/2016/01/drugs-off-patent/
![Page 5: NEW DRUG UPDATE 2016 - cdn.ymaws.com · • New Drug Update 2016 is accredited for 1.5 contact hours – Pharmacists ACPE 0154-0000-16-010-L01-P – Technicians ACPE 0154-0000-16-010-L01-T](https://reader033.vdocument.in/reader033/viewer/2022060600/60543e4917da3737fa6a5a6a/html5/thumbnails/5.jpg)
FDADrugApprovalsin2015/2016• 2015– 45newdrugapprovals(mostsince1950)
– 16withnovelMOA(36%)– Almost½usedforrarediseases
– Expeditedreviewgrantedto60%ofnewdrugs
• 2016– 29drugsapprovedsofar
hap://www.forbes.com/sites/bernardmunos/2016/01/04/2015-new-drug-approvals-hit-66-year-high/#7b1b86721044hap://cen.acs.org/arIcles/94/i5/Year-New-Drugs.html
![Page 6: NEW DRUG UPDATE 2016 - cdn.ymaws.com · • New Drug Update 2016 is accredited for 1.5 contact hours – Pharmacists ACPE 0154-0000-16-010-L01-P – Technicians ACPE 0154-0000-16-010-L01-T](https://reader033.vdocument.in/reader033/viewer/2022060600/60543e4917da3737fa6a5a6a/html5/thumbnails/6.jpg)
IDARUCIZUMAB(PRAXIBIND®-BOEHRINGER-INGELHEIM)
![Page 7: NEW DRUG UPDATE 2016 - cdn.ymaws.com · • New Drug Update 2016 is accredited for 1.5 contact hours – Pharmacists ACPE 0154-0000-16-010-L01-P – Technicians ACPE 0154-0000-16-010-L01-T](https://reader033.vdocument.in/reader033/viewer/2022060600/60543e4917da3737fa6a5a6a/html5/thumbnails/7.jpg)
Idarucizumab• Dabigatranreversalagent– Life-threateningoruncontrolledbleeding– Emergent/urgentprocedure
![Page 8: NEW DRUG UPDATE 2016 - cdn.ymaws.com · • New Drug Update 2016 is accredited for 1.5 contact hours – Pharmacists ACPE 0154-0000-16-010-L01-P – Technicians ACPE 0154-0000-16-010-L01-T](https://reader033.vdocument.in/reader033/viewer/2022060600/60543e4917da3737fa6a5a6a/html5/thumbnails/8.jpg)
Idarucizumab• HumanizedmonoclonalanIbodyfragment(Fab)– Bindsspecificallytodabigatran&dabigatranmetabolites• 350Xaffinityfordabigatranvs.thrombin
– ReversesanIcoagulanteffects• Onsetinminutes• HemostasIs~11½hours
– Doesnotinterferewithclorngproteinsdirectly
JACC2016;67:1654
![Page 9: NEW DRUG UPDATE 2016 - cdn.ymaws.com · • New Drug Update 2016 is accredited for 1.5 contact hours – Pharmacists ACPE 0154-0000-16-010-L01-P – Technicians ACPE 0154-0000-16-010-L01-T](https://reader033.vdocument.in/reader033/viewer/2022060600/60543e4917da3737fa6a5a6a/html5/thumbnails/9.jpg)
Idarucizumab• Dosing– 5gIV• Pushorinfusion• 2X2.5g(50mL)
– ≤15minutesapart
– ConInuedorrepeatbleeding• Dataon2nddoselimited
Anesthes2015;123:A21
![Page 10: NEW DRUG UPDATE 2016 - cdn.ymaws.com · • New Drug Update 2016 is accredited for 1.5 contact hours – Pharmacists ACPE 0154-0000-16-010-L01-P – Technicians ACPE 0154-0000-16-010-L01-T](https://reader033.vdocument.in/reader033/viewer/2022060600/60543e4917da3737fa6a5a6a/html5/thumbnails/10.jpg)
Idarucizumab• Adverseeffects– Headache– Hypokalemia– Delirium– PotenIalimmunereacIon
– ThromboIcrisk• Noincreaseoverbaseline
Anesthes2015;123:A21
![Page 11: NEW DRUG UPDATE 2016 - cdn.ymaws.com · • New Drug Update 2016 is accredited for 1.5 contact hours – Pharmacists ACPE 0154-0000-16-010-L01-P – Technicians ACPE 0154-0000-16-010-L01-T](https://reader033.vdocument.in/reader033/viewer/2022060600/60543e4917da3737fa6a5a6a/html5/thumbnails/11.jpg)
Idarucizumab• SomesubjectsinRE-VERSEAD™trial– Re-elevaIonofbleedrisk
– RedistribuIonofdabigatranfromIssuestoplasma
IdarucizumabprescribinginformaIon
![Page 12: NEW DRUG UPDATE 2016 - cdn.ymaws.com · • New Drug Update 2016 is accredited for 1.5 contact hours – Pharmacists ACPE 0154-0000-16-010-L01-P – Technicians ACPE 0154-0000-16-010-L01-T](https://reader033.vdocument.in/reader033/viewer/2022060600/60543e4917da3737fa6a5a6a/html5/thumbnails/12.jpg)
CEFTAZIDIME/AVIBACTAM(AVYCAZ®-ALLERGAN/ASTRAZENECA)
![Page 13: NEW DRUG UPDATE 2016 - cdn.ymaws.com · • New Drug Update 2016 is accredited for 1.5 contact hours – Pharmacists ACPE 0154-0000-16-010-L01-P – Technicians ACPE 0154-0000-16-010-L01-T](https://reader033.vdocument.in/reader033/viewer/2022060600/60543e4917da3737fa6a5a6a/html5/thumbnails/13.jpg)
Cexazidime/Avibactam• 50,000FootView– AnIbioIcwithnovelbetalactamaseinhibitorusedfor“Armageddon”gram–negaIvepathogens
• DrugClass– CephalosporinclassanIbioIc
• FDAIndicaIons– Complicatedintra–abdominalinfecIons
• IncombinaIonw/metronidazole
– ComplicatedurinarytractinfecIons• IncombinaIonw/metronidazole
![Page 14: NEW DRUG UPDATE 2016 - cdn.ymaws.com · • New Drug Update 2016 is accredited for 1.5 contact hours – Pharmacists ACPE 0154-0000-16-010-L01-P – Technicians ACPE 0154-0000-16-010-L01-T](https://reader033.vdocument.in/reader033/viewer/2022060600/60543e4917da3737fa6a5a6a/html5/thumbnails/14.jpg)
Cexazidime/Avibactam• MOA– Cexazidime
• 3rdgeneraIoncephalosporinonmarketsince1980s• Cellwallinhibitor(bindsPBPs)• AcIvityvs.Pseudomonasspp.
– Avibactam• Betalactamaseinhibitor• AcIvevs.AmpC,ESBL,KPC• NotacIvevs.metallo–betalactamases
![Page 15: NEW DRUG UPDATE 2016 - cdn.ymaws.com · • New Drug Update 2016 is accredited for 1.5 contact hours – Pharmacists ACPE 0154-0000-16-010-L01-P – Technicians ACPE 0154-0000-16-010-L01-T](https://reader033.vdocument.in/reader033/viewer/2022060600/60543e4917da3737fa6a5a6a/html5/thumbnails/15.jpg)
Cexazidime/Avibactam• Dosing(IVonly)– 2.5gevery8hoursincombinaIonwithmetronidazole– For5–14daysincIAI– For7–14daysincUTI
• Contains2gofcexazidimeand0.5gofavibactam• Dosingbasedonthesumofingredients(e.g.2.5g)• Requiresrenaldoseadjustmentw/CrCl<50mL/min
• Administeraxerdialysis• Administerovertwohours
![Page 16: NEW DRUG UPDATE 2016 - cdn.ymaws.com · • New Drug Update 2016 is accredited for 1.5 contact hours – Pharmacists ACPE 0154-0000-16-010-L01-P – Technicians ACPE 0154-0000-16-010-L01-T](https://reader033.vdocument.in/reader033/viewer/2022060600/60543e4917da3737fa6a5a6a/html5/thumbnails/16.jpg)
Cexazidime/Avibactam• ClinicalEvidence– cIAI(LucasIJAC2013;MazuskiCID2016)
• Cexaz/avi+metrononinferiortomeropenem
– cUTI(VazquezCurrMedResOpin2012)• Cexaz/avi+metrononinferiortoimipenem/cilastaIn
• SafetyData– NonspecificGIsymptoms/headache– OnecaseofincreasedLFTs– Welltolerated
JAC2013;68:1183-92CID2016;62(11):1380-9
CurrMedResOpin2012;28(12):1921-31
![Page 17: NEW DRUG UPDATE 2016 - cdn.ymaws.com · • New Drug Update 2016 is accredited for 1.5 contact hours – Pharmacists ACPE 0154-0000-16-010-L01-P – Technicians ACPE 0154-0000-16-010-L01-T](https://reader033.vdocument.in/reader033/viewer/2022060600/60543e4917da3737fa6a5a6a/html5/thumbnails/17.jpg)
Cexazidime/Avibactam• DrugInteracIons– MayincreaseeffectofVKAs– Levelsdecreasedbyprobenecid
• WarningsandPrecauIons– Neurotoxicityw/highdose(βlactam,duh)
• PregnancyCategoryB/excretedinbreastmilk• ContraindicaIons– HypersensiIvitytocephalosporins
![Page 18: NEW DRUG UPDATE 2016 - cdn.ymaws.com · • New Drug Update 2016 is accredited for 1.5 contact hours – Pharmacists ACPE 0154-0000-16-010-L01-P – Technicians ACPE 0154-0000-16-010-L01-T](https://reader033.vdocument.in/reader033/viewer/2022060600/60543e4917da3737fa6a5a6a/html5/thumbnails/18.jpg)
Cexazidime/Avibactam• MarketNiche– SeriousgramnegaIveinfecIons– ContainingKPCbetalactamases– SparingtoxicalternaIves(i.e.colisIn)– IndicatedincIAIandcUTI,butlikelytobeusedofflabelindiresituaIons
• Pricing:$1,000/dayAWP
![Page 19: NEW DRUG UPDATE 2016 - cdn.ymaws.com · • New Drug Update 2016 is accredited for 1.5 contact hours – Pharmacists ACPE 0154-0000-16-010-L01-P – Technicians ACPE 0154-0000-16-010-L01-T](https://reader033.vdocument.in/reader033/viewer/2022060600/60543e4917da3737fa6a5a6a/html5/thumbnails/19.jpg)
SUGAMMADEX(BRIDION®-MERCK)
![Page 20: NEW DRUG UPDATE 2016 - cdn.ymaws.com · • New Drug Update 2016 is accredited for 1.5 contact hours – Pharmacists ACPE 0154-0000-16-010-L01-P – Technicians ACPE 0154-0000-16-010-L01-T](https://reader033.vdocument.in/reader033/viewer/2022060600/60543e4917da3737fa6a5a6a/html5/thumbnails/20.jpg)
Sugammadex• AnIdote– SelecIvereversalofaminosteroidalnon-depolarizingneuromuscularblockers• Rocuronium>vecuronium>>pancuronium
• MechanismofacIon– Bindsrocuronium1:1
• Decreasesfreerocuronium– Formsplasmagradient
• BoundrocuroniumdiffusesfromneuromuscularjuncIon– Newlyfreerocuroniumbindstosugammadex
• Water-solublecomplex– Excretedunchangedintheurine
![Page 21: NEW DRUG UPDATE 2016 - cdn.ymaws.com · • New Drug Update 2016 is accredited for 1.5 contact hours – Pharmacists ACPE 0154-0000-16-010-L01-P – Technicians ACPE 0154-0000-16-010-L01-T](https://reader033.vdocument.in/reader033/viewer/2022060600/60543e4917da3737fa6a5a6a/html5/thumbnails/21.jpg)
Sugammadex• Dosing– RouInereversalofneuromuscularblockade
• IVassingledosebasedonactualbodyweight– Deepblockade=4mg/kg– Moderateblockade=2mg/kg
– Immediatereversalofneuromuscularblockade• IV16mg/kg
– Within3minutesof1.2mg/kgofrocuroniumdose
– WaitImesforre-administraIonvary• Ifimmediateneuromuscularblockaderequiredaxersugammadex– Canusenon-steroidalagent
![Page 22: NEW DRUG UPDATE 2016 - cdn.ymaws.com · • New Drug Update 2016 is accredited for 1.5 contact hours – Pharmacists ACPE 0154-0000-16-010-L01-P – Technicians ACPE 0154-0000-16-010-L01-T](https://reader033.vdocument.in/reader033/viewer/2022060600/60543e4917da3737fa6a5a6a/html5/thumbnails/22.jpg)
Sugammadex• DruginteracIons– Displacementbysteroid-likestructures– Toremifene– Fusidicacid– Progesterones?
• Monitorforrecurrenceofneuromuscularblockade
![Page 23: NEW DRUG UPDATE 2016 - cdn.ymaws.com · • New Drug Update 2016 is accredited for 1.5 contact hours – Pharmacists ACPE 0154-0000-16-010-L01-P – Technicians ACPE 0154-0000-16-010-L01-T](https://reader033.vdocument.in/reader033/viewer/2022060600/60543e4917da3737fa6a5a6a/html5/thumbnails/23.jpg)
PATIROMER(VELTASSA®-RELYPSA)
![Page 24: NEW DRUG UPDATE 2016 - cdn.ymaws.com · • New Drug Update 2016 is accredited for 1.5 contact hours – Pharmacists ACPE 0154-0000-16-010-L01-P – Technicians ACPE 0154-0000-16-010-L01-T](https://reader033.vdocument.in/reader033/viewer/2022060600/60543e4917da3737fa6a5a6a/html5/thumbnails/24.jpg)
PaIromer• AnIdoteforhyperkalemia– ForchronicadministraIonispaIentswhorequireRAASinhibitors
– Notforemergentuse
• Mechanism– Non-absorbablecaIon-exchangepolymer• Calcium/sorbitol
![Page 25: NEW DRUG UPDATE 2016 - cdn.ymaws.com · • New Drug Update 2016 is accredited for 1.5 contact hours – Pharmacists ACPE 0154-0000-16-010-L01-P – Technicians ACPE 0154-0000-16-010-L01-T](https://reader033.vdocument.in/reader033/viewer/2022060600/60543e4917da3737fa6a5a6a/html5/thumbnails/25.jpg)
PaIromer• Dosing– 8.4goraldaily
• Mixpowderwithwater;drinkimmediately• Takewithfood• Adjust≥weekly;maxdose25.2gperday
• DruginteracIons– Boxedwarning
• Bindsoraldrugs—separatedosesby6hoursbefore/axer• Adverseeffects– Hypomagnesemia– GI
• MaycauseconsIpaIonordiarrhea• IneffecIveinsevereconsIpaIon
![Page 26: NEW DRUG UPDATE 2016 - cdn.ymaws.com · • New Drug Update 2016 is accredited for 1.5 contact hours – Pharmacists ACPE 0154-0000-16-010-L01-P – Technicians ACPE 0154-0000-16-010-L01-T](https://reader033.vdocument.in/reader033/viewer/2022060600/60543e4917da3737fa6a5a6a/html5/thumbnails/26.jpg)
ROLAPITANT(VARUBI®-TESARO)
![Page 27: NEW DRUG UPDATE 2016 - cdn.ymaws.com · • New Drug Update 2016 is accredited for 1.5 contact hours – Pharmacists ACPE 0154-0000-16-010-L01-P – Technicians ACPE 0154-0000-16-010-L01-T](https://reader033.vdocument.in/reader033/viewer/2022060600/60543e4917da3737fa6a5a6a/html5/thumbnails/27.jpg)
Rolapitant• AnI-emeIc– IndicatedforprevenIonofdelayedchemotherapy-inducednausea&vomiIng(CINV)
• MechanismofacIon– SubstanceP/neurokinin1(NK1)receptorblocker• SubstancePsImulateschemoreceptortriggerzonecausingnausea/vomiIng
![Page 28: NEW DRUG UPDATE 2016 - cdn.ymaws.com · • New Drug Update 2016 is accredited for 1.5 contact hours – Pharmacists ACPE 0154-0000-16-010-L01-P – Technicians ACPE 0154-0000-16-010-L01-T](https://reader033.vdocument.in/reader033/viewer/2022060600/60543e4917da3737fa6a5a6a/html5/thumbnails/28.jpg)
Rolapitant• Highlyemetogenictherapy
– 180mg1-2hourspriortotherapyonday1only• Givewithdexamethasone&5-HT3regimen
• DonotgivemorefrequentlythanQ2weeks
• Moderatelyemetogenictherapy– 180mg1-2hourspriortotherapyonday1only• DonotgivemorefrequentlythanQ2weeks
• t½~7days• MetabolizedviaCYP3A4to
acIvemetabolites
![Page 29: NEW DRUG UPDATE 2016 - cdn.ymaws.com · • New Drug Update 2016 is accredited for 1.5 contact hours – Pharmacists ACPE 0154-0000-16-010-L01-P – Technicians ACPE 0154-0000-16-010-L01-T](https://reader033.vdocument.in/reader033/viewer/2022060600/60543e4917da3737fa6a5a6a/html5/thumbnails/29.jpg)
ISAVUCONAZOLECRESEMBA®-ASTELLAS
![Page 30: NEW DRUG UPDATE 2016 - cdn.ymaws.com · • New Drug Update 2016 is accredited for 1.5 contact hours – Pharmacists ACPE 0154-0000-16-010-L01-P – Technicians ACPE 0154-0000-16-010-L01-T](https://reader033.vdocument.in/reader033/viewer/2022060600/60543e4917da3737fa6a5a6a/html5/thumbnails/30.jpg)
Isavuconazole• 50,000FootView– AnIfungalw/acIvityagainstAspergillusandMucormycosesspp.
• DrugClass– AzoleanIfungal
• FDAIndicaIons– InvasiveAspergillosis– InvasiveMucormycosis
![Page 31: NEW DRUG UPDATE 2016 - cdn.ymaws.com · • New Drug Update 2016 is accredited for 1.5 contact hours – Pharmacists ACPE 0154-0000-16-010-L01-P – Technicians ACPE 0154-0000-16-010-L01-T](https://reader033.vdocument.in/reader033/viewer/2022060600/60543e4917da3737fa6a5a6a/html5/thumbnails/31.jpg)
Isavuconazole• MOA– InhibitsCYP450–dependent14α–lanosterol– EssenIalforfungalcellmembraneformaIon– AcIveagainstyeasts,molds
• Administeredasprodrug– 186mgisavuconazoniumsulfate=100mgisavuconazole
• Dosing– LoadingDose:372mgq8hoursx6doses– MaintenanceDose:200mgoncedaily
![Page 32: NEW DRUG UPDATE 2016 - cdn.ymaws.com · • New Drug Update 2016 is accredited for 1.5 contact hours – Pharmacists ACPE 0154-0000-16-010-L01-P – Technicians ACPE 0154-0000-16-010-L01-T](https://reader033.vdocument.in/reader033/viewer/2022060600/60543e4917da3737fa6a5a6a/html5/thumbnails/32.jpg)
Isavuconazole• AvailableIVandPO;98%bioavailability• Verylonghalf–life=>4days• MetabolizedviaCYP3A4– Notrecommendedinadvancedliverdisease
• Eliminatedviafeces– Noneedforrenaldoseadjustment– NotgoodforUTItreatment
![Page 33: NEW DRUG UPDATE 2016 - cdn.ymaws.com · • New Drug Update 2016 is accredited for 1.5 contact hours – Pharmacists ACPE 0154-0000-16-010-L01-P – Technicians ACPE 0154-0000-16-010-L01-T](https://reader033.vdocument.in/reader033/viewer/2022060600/60543e4917da3737fa6a5a6a/html5/thumbnails/33.jpg)
Isavuconazole• ClinicalEvidence– SECURE:non–inferiortovoriconazoleforaspergillus– Preliminarydatavs.Mucormycosesindicatesimilarmortalitytohistoricaldata(35%)
– LimiteddataagainstFusarium/Endemicmolds• SafetyData– NonspecificGIsymptoms– Novisualdisturbanceslikevoriconazole– LiverenzymeelevaIons(it’sanazole)– ShortensQTc– InfusionreacIonsinafewpaIentsàusefilter
![Page 34: NEW DRUG UPDATE 2016 - cdn.ymaws.com · • New Drug Update 2016 is accredited for 1.5 contact hours – Pharmacists ACPE 0154-0000-16-010-L01-P – Technicians ACPE 0154-0000-16-010-L01-T](https://reader033.vdocument.in/reader033/viewer/2022060600/60543e4917da3737fa6a5a6a/html5/thumbnails/34.jpg)
Isavuconazole• DrugInteracIons– CYP3A4àrifampin,CBZ,immunosuppressants
• WarningsandPrecauIons– HepaIceffects(10xLFTsin1.2%)– InfusionrelatedreacIons
• PregnancyCategoryC/excretedinbreastmilk– Higherperinatalmortalityinratsw/halfmaintenancedose
• ContraindicaIons– Useofstrong3A4inhibitors/inducers– FamilialshortQTcsyndrome
![Page 35: NEW DRUG UPDATE 2016 - cdn.ymaws.com · • New Drug Update 2016 is accredited for 1.5 contact hours – Pharmacists ACPE 0154-0000-16-010-L01-P – Technicians ACPE 0154-0000-16-010-L01-T](https://reader033.vdocument.in/reader033/viewer/2022060600/60543e4917da3737fa6a5a6a/html5/thumbnails/35.jpg)
Isavuconazole• MarketNiche– AlternaIvetovoriconazoleforAspergillosis
• Beaerbioavailability• Beaersideeffectprofile
– AlternaIvetoposaconazole/anotheropIonagainstMucormycoses• Beaerbioavailability
• Pricing– IV:Onedose=$285– POOnedose=$168
![Page 36: NEW DRUG UPDATE 2016 - cdn.ymaws.com · • New Drug Update 2016 is accredited for 1.5 contact hours – Pharmacists ACPE 0154-0000-16-010-L01-P – Technicians ACPE 0154-0000-16-010-L01-T](https://reader033.vdocument.in/reader033/viewer/2022060600/60543e4917da3737fa6a5a6a/html5/thumbnails/36.jpg)
INSULINDEGLUDECTRESIBA®–NOVONORDISK
![Page 37: NEW DRUG UPDATE 2016 - cdn.ymaws.com · • New Drug Update 2016 is accredited for 1.5 contact hours – Pharmacists ACPE 0154-0000-16-010-L01-P – Technicians ACPE 0154-0000-16-010-L01-T](https://reader033.vdocument.in/reader033/viewer/2022060600/60543e4917da3737fa6a5a6a/html5/thumbnails/37.jpg)
InsulinDegludec• 50,000FootView– Ultra–longacIngbasalinsulinwithpromisestoreducehypoglycemia
• FDAIndicaIons– ImprovedglucosecontrolinType1andType2diabetesmellitus
![Page 38: NEW DRUG UPDATE 2016 - cdn.ymaws.com · • New Drug Update 2016 is accredited for 1.5 contact hours – Pharmacists ACPE 0154-0000-16-010-L01-P – Technicians ACPE 0154-0000-16-010-L01-T](https://reader033.vdocument.in/reader033/viewer/2022060600/60543e4917da3737fa6a5a6a/html5/thumbnails/38.jpg)
InsulinDegludec• Dosing– T1DM
• Insulin–naïve:1/3to1/2oftotaldailyinsulindose(usually0.2–0.4units/kg)givenoncedaily• Insulin–experienced:Samedoseattotaldailybasaldose
– T2DM• Insulin–naïve:10unitsoncedaily• Insulin–experienced:Samedoseattotaldailybasaldose
– Ensure8hoursbetweenconsecuIvedoses
![Page 39: NEW DRUG UPDATE 2016 - cdn.ymaws.com · • New Drug Update 2016 is accredited for 1.5 contact hours – Pharmacists ACPE 0154-0000-16-010-L01-P – Technicians ACPE 0154-0000-16-010-L01-T](https://reader033.vdocument.in/reader033/viewer/2022060600/60543e4917da3737fa6a5a6a/html5/thumbnails/39.jpg)
InsulinDegludec• Pharmacology– UsesphenolinformulaIontoformsolubledihexamers– Onceinjectedsubcutaneously,phenoldisperses,andself–associatesintolargermulIhexamers
– Individualinsulinmoleculesgraduallydissociateasmonomers
• KineIcs– SteadyabsorpIon– Zero–orderkineIcs– Onset=30–90minutes– Half–life=25hours– DuraIonofacIon>42hours
![Page 40: NEW DRUG UPDATE 2016 - cdn.ymaws.com · • New Drug Update 2016 is accredited for 1.5 contact hours – Pharmacists ACPE 0154-0000-16-010-L01-P – Technicians ACPE 0154-0000-16-010-L01-T](https://reader033.vdocument.in/reader033/viewer/2022060600/60543e4917da3737fa6a5a6a/html5/thumbnails/40.jpg)
InsulinDegludec• Differencesfromdetemirandglargine– LessvariabilityinbloodglucoseloweringfrominjecIontoinjecIon
– Abilitytoco-formulatewithbolusinsulins• Glargineformsprecipitate• Detemirlowerseffectofbolusinsulin• Degludecincombow/aspartindevelopment
– Increasedflexibilityindosing• ChangesininjecIonImew/degludecdonotadverselyeffectglucosecontrol
– StabilityinhepaIc/renaldisease
![Page 41: NEW DRUG UPDATE 2016 - cdn.ymaws.com · • New Drug Update 2016 is accredited for 1.5 contact hours – Pharmacists ACPE 0154-0000-16-010-L01-P – Technicians ACPE 0154-0000-16-010-L01-T](https://reader033.vdocument.in/reader033/viewer/2022060600/60543e4917da3737fa6a5a6a/html5/thumbnails/41.jpg)
InsulinDegludec
BEGINBasal–BolusType1Degludec Glargine
A1cReducIon 0.4% 0.39%Nocturnal
Hypoglycemia 3.9% 5.2%
Lancet2012;379(9825):1489-97Lancet2012;379(9825):1498-1507
BEGINBasal–BolusType2Degludec Glargine
A1cReducIon 1.1% 1.18%Overall
Hypoglycemia 11% 13.6%
![Page 42: NEW DRUG UPDATE 2016 - cdn.ymaws.com · • New Drug Update 2016 is accredited for 1.5 contact hours – Pharmacists ACPE 0154-0000-16-010-L01-P – Technicians ACPE 0154-0000-16-010-L01-T](https://reader033.vdocument.in/reader033/viewer/2022060600/60543e4917da3737fa6a5a6a/html5/thumbnails/42.jpg)
InsulinDegludec• WarningsandPrecauIons– Hypoglycemia/hypokalemia– NotforuseinDKA
• PregnancyCategoryC– Notstudiedinpregnantwoman/animalstudiesrevealedadverseeventsduetomaternalhypoglycemia
• Excretedinbreastmilk• OpImaltransiIondosingfromotherlong–acInginsulinsyettobeelucidated
• Storage:Stablefor8weeksatroomtemperature
![Page 43: NEW DRUG UPDATE 2016 - cdn.ymaws.com · • New Drug Update 2016 is accredited for 1.5 contact hours – Pharmacists ACPE 0154-0000-16-010-L01-P – Technicians ACPE 0154-0000-16-010-L01-T](https://reader033.vdocument.in/reader033/viewer/2022060600/60543e4917da3737fa6a5a6a/html5/thumbnails/43.jpg)
InsulinDegludec• MarketNiche– Alreadyco–formulatedwithinsulinaspart
• IDegAspàRyzodeg70/30®
– TheFuture• IDegLiraàliragluIde/degludecco–formulaIon
• Pricing– 100units/mL(3mL)=$100– 200units/mL(3mL)=$213
![Page 44: NEW DRUG UPDATE 2016 - cdn.ymaws.com · • New Drug Update 2016 is accredited for 1.5 contact hours – Pharmacists ACPE 0154-0000-16-010-L01-P – Technicians ACPE 0154-0000-16-010-L01-T](https://reader033.vdocument.in/reader033/viewer/2022060600/60543e4917da3737fa6a5a6a/html5/thumbnails/44.jpg)
SELEXIPAG(UPTRAVI®–ACTELION)
![Page 45: NEW DRUG UPDATE 2016 - cdn.ymaws.com · • New Drug Update 2016 is accredited for 1.5 contact hours – Pharmacists ACPE 0154-0000-16-010-L01-P – Technicians ACPE 0154-0000-16-010-L01-T](https://reader033.vdocument.in/reader033/viewer/2022060600/60543e4917da3737fa6a5a6a/html5/thumbnails/45.jpg)
Selexipag• 50,000FootView– NewPAHdrugforearlystagedisease(WHOII/III)
• MOA– ProstacyclinIPreceptoragonistàrelaxedsmoothmuscle
– LessGIeffectsthanotherPAHdrugs• Dosing– Startedat200mcgtwicedaily– Titratedweeklyupto1600mcgtwicedaily– Ifdosemissedfor>3days,restartatlowerdose
• AvoidgemfibrozilincombinaIon• Onetablet=$155
![Page 46: NEW DRUG UPDATE 2016 - cdn.ymaws.com · • New Drug Update 2016 is accredited for 1.5 contact hours – Pharmacists ACPE 0154-0000-16-010-L01-P – Technicians ACPE 0154-0000-16-010-L01-T](https://reader033.vdocument.in/reader033/viewer/2022060600/60543e4917da3737fa6a5a6a/html5/thumbnails/46.jpg)
PIMAVANSERIN(NUPLAZID®–ACADIA)
![Page 47: NEW DRUG UPDATE 2016 - cdn.ymaws.com · • New Drug Update 2016 is accredited for 1.5 contact hours – Pharmacists ACPE 0154-0000-16-010-L01-P – Technicians ACPE 0154-0000-16-010-L01-T](https://reader033.vdocument.in/reader033/viewer/2022060600/60543e4917da3737fa6a5a6a/html5/thumbnails/47.jpg)
Pimavanserin• 50,000FootView– NondopamineatypicalanI-psychoIcforParkinson’spsychosis
• MOA– Inverseagonistofserotonin5-HT2A– ExciIngtargetforpsychosisofdifferentdiseases
• Dosing– 34mgQDay(1/2dosew/Strong3A4inhibitors)
• CanprolongQTcinterval
![Page 48: NEW DRUG UPDATE 2016 - cdn.ymaws.com · • New Drug Update 2016 is accredited for 1.5 contact hours – Pharmacists ACPE 0154-0000-16-010-L01-P – Technicians ACPE 0154-0000-16-010-L01-T](https://reader033.vdocument.in/reader033/viewer/2022060600/60543e4917da3737fa6a5a6a/html5/thumbnails/48.jpg)
AnIpsychoIcReceptorAcIvity
NeurochemRes2014;39:2008-17
![Page 49: NEW DRUG UPDATE 2016 - cdn.ymaws.com · • New Drug Update 2016 is accredited for 1.5 contact hours – Pharmacists ACPE 0154-0000-16-010-L01-P – Technicians ACPE 0154-0000-16-010-L01-T](https://reader033.vdocument.in/reader033/viewer/2022060600/60543e4917da3737fa6a5a6a/html5/thumbnails/49.jpg)
SECUKINUMAB(COSENTYX®–NOVARTIS)
NeurochemRes2014
![Page 50: NEW DRUG UPDATE 2016 - cdn.ymaws.com · • New Drug Update 2016 is accredited for 1.5 contact hours – Pharmacists ACPE 0154-0000-16-010-L01-P – Technicians ACPE 0154-0000-16-010-L01-T](https://reader033.vdocument.in/reader033/viewer/2022060600/60543e4917da3737fa6a5a6a/html5/thumbnails/50.jpg)
Secukinumab• 50,000FootView– AnIbodyinjectableformoderate–severeplaquepsoriasis,ankylosingspondyliIs,andpsoriaIcarthriIs
• MOA– IL-17AmonocolonalanIbody
• Dosing– Psoriasis:300mgSCQWkx5doses,thenQmonth– AS/PA:150mgSCQWkx5doses,thenQmonth
• IncreasesriskofinfecIon/RequiresTBtestNeurochemRes2014
![Page 51: NEW DRUG UPDATE 2016 - cdn.ymaws.com · • New Drug Update 2016 is accredited for 1.5 contact hours – Pharmacists ACPE 0154-0000-16-010-L01-P – Technicians ACPE 0154-0000-16-010-L01-T](https://reader033.vdocument.in/reader033/viewer/2022060600/60543e4917da3737fa6a5a6a/html5/thumbnails/51.jpg)
CANGRELOR(KENGREAL®-THEMEDICINECO.)
![Page 52: NEW DRUG UPDATE 2016 - cdn.ymaws.com · • New Drug Update 2016 is accredited for 1.5 contact hours – Pharmacists ACPE 0154-0000-16-010-L01-P – Technicians ACPE 0154-0000-16-010-L01-T](https://reader033.vdocument.in/reader033/viewer/2022060600/60543e4917da3737fa6a5a6a/html5/thumbnails/52.jpg)
Cangrelor• Plateletinhibitor– Decreasesriskofperi-proceduralmyocardialinfarcIonduringpercutaneouscoronaryintervenIon(PCI)
• Mechanism– Direct-acIngP2Y12inhibitor• IrreversiblyinhibitsADPreceptor
NatRevCardol2011;8:547
![Page 53: NEW DRUG UPDATE 2016 - cdn.ymaws.com · • New Drug Update 2016 is accredited for 1.5 contact hours – Pharmacists ACPE 0154-0000-16-010-L01-P – Technicians ACPE 0154-0000-16-010-L01-T](https://reader033.vdocument.in/reader033/viewer/2022060600/60543e4917da3737fa6a5a6a/html5/thumbnails/53.jpg)
Cangrelor• IVadministraIon– 30mcg/kgbolus30minutepriortoPCI
– 4mcg/kg/minuteinfusionduringprocudure• ConInueatleast2hours
NatRevCardol2011;8:547
![Page 54: NEW DRUG UPDATE 2016 - cdn.ymaws.com · • New Drug Update 2016 is accredited for 1.5 contact hours – Pharmacists ACPE 0154-0000-16-010-L01-P – Technicians ACPE 0154-0000-16-010-L01-T](https://reader033.vdocument.in/reader033/viewer/2022060600/60543e4917da3737fa6a5a6a/html5/thumbnails/54.jpg)
Cangrelor• TransiIontooralagent– 600mgclopidogrelor60mgprasugrel• Immediatelyatendofinfusion;doNOTgivepriortodisconInuaIonofinfusion
– 180mgIcagrelor• Immediatelyatendof,orduringinfusion
• Rapidonset/offset– DonotusewithgpIIB/IIIaP2Y12inhibitor
NatRevCardol2011;8:547
![Page 55: NEW DRUG UPDATE 2016 - cdn.ymaws.com · • New Drug Update 2016 is accredited for 1.5 contact hours – Pharmacists ACPE 0154-0000-16-010-L01-P – Technicians ACPE 0154-0000-16-010-L01-T](https://reader033.vdocument.in/reader033/viewer/2022060600/60543e4917da3737fa6a5a6a/html5/thumbnails/55.jpg)
SACUBATRIL/VALSARTAN(ENTRESTO®-NOVARTIS)
![Page 56: NEW DRUG UPDATE 2016 - cdn.ymaws.com · • New Drug Update 2016 is accredited for 1.5 contact hours – Pharmacists ACPE 0154-0000-16-010-L01-P – Technicians ACPE 0154-0000-16-010-L01-T](https://reader033.vdocument.in/reader033/viewer/2022060600/60543e4917da3737fa6a5a6a/html5/thumbnails/56.jpg)
• DegradesvasoacIvepepIdes– NatriureIcpepIdes– Bradykinin– Others
Neprilysin
![Page 57: NEW DRUG UPDATE 2016 - cdn.ymaws.com · • New Drug Update 2016 is accredited for 1.5 contact hours – Pharmacists ACPE 0154-0000-16-010-L01-P – Technicians ACPE 0154-0000-16-010-L01-T](https://reader033.vdocument.in/reader033/viewer/2022060600/60543e4917da3737fa6a5a6a/html5/thumbnails/57.jpg)
• IncreasesnaIureIcpepIdes&opposesneurohormonalacIvity
NeprilysinInhibiIon
![Page 58: NEW DRUG UPDATE 2016 - cdn.ymaws.com · • New Drug Update 2016 is accredited for 1.5 contact hours – Pharmacists ACPE 0154-0000-16-010-L01-P – Technicians ACPE 0154-0000-16-010-L01-T](https://reader033.vdocument.in/reader033/viewer/2022060600/60543e4917da3737fa6a5a6a/html5/thumbnails/58.jpg)
PARADIGM-HF• HFrEF– LCZ696(valsartan&neprilysininhibitor)vs.enalapril
• Methods– Double-blindRCT• N=8442classII-IVHF• EF≤40%
– Primaryoutcome• CompositeofCVdeathorhospitalizaIonforHF
NEnglJMed2014;371;11
![Page 59: NEW DRUG UPDATE 2016 - cdn.ymaws.com · • New Drug Update 2016 is accredited for 1.5 contact hours – Pharmacists ACPE 0154-0000-16-010-L01-P – Technicians ACPE 0154-0000-16-010-L01-T](https://reader033.vdocument.in/reader033/viewer/2022060600/60543e4917da3737fa6a5a6a/html5/thumbnails/59.jpg)
PARADIGM-HF• Results
– Trialstopped@meanf/u27months
– Primaryoutcome• LCZ696=914(21.8%)vs.enalapril=1117(26.5%)– HazardraIo0.80;95%CI0.73
to0.87;P<0.001
– LCZ696group• >hypotension,non-seriousangioedema
• <renalimpairment,hyperkalemia,cough
• Conclusions– LCZ696superiortoenalaprilinreducingriskofdeath&hospitalizaIonforHF
NEnglJMed2014;371;11
![Page 60: NEW DRUG UPDATE 2016 - cdn.ymaws.com · • New Drug Update 2016 is accredited for 1.5 contact hours – Pharmacists ACPE 0154-0000-16-010-L01-P – Technicians ACPE 0154-0000-16-010-L01-T](https://reader033.vdocument.in/reader033/viewer/2022060600/60543e4917da3737fa6a5a6a/html5/thumbnails/60.jpg)
Sacubatril&Valsartan(Entresto®)• PotenIaltoreplaceACEinhibitor– ContraindicatedwithACEI,pregnancy– HFrEFNYHAclassII-IV
• LVEF≤40%• Stable
– SymptomaIcdespiteopImaltherapy
• Dosing– Sacubatril/valsartan
• 24mg/26mg=50mg(~40mgvalsartan)• 49mg/51mg=100mg(~80mgvalsartan)• 97mg/103mg=200mg(~160mgvalsartan)
![Page 61: NEW DRUG UPDATE 2016 - cdn.ymaws.com · • New Drug Update 2016 is accredited for 1.5 contact hours – Pharmacists ACPE 0154-0000-16-010-L01-P – Technicians ACPE 0154-0000-16-010-L01-T](https://reader033.vdocument.in/reader033/viewer/2022060600/60543e4917da3737fa6a5a6a/html5/thumbnails/61.jpg)
IVABRADINE(CORLANOR®-AMGEN)
![Page 62: NEW DRUG UPDATE 2016 - cdn.ymaws.com · • New Drug Update 2016 is accredited for 1.5 contact hours – Pharmacists ACPE 0154-0000-16-010-L01-P – Technicians ACPE 0154-0000-16-010-L01-T](https://reader033.vdocument.in/reader033/viewer/2022060600/60543e4917da3737fa6a5a6a/html5/thumbnails/62.jpg)
HeartRateControl• HFrEFpaIents– ElevatedHR
• Increaseinmorbidity&mortality
• PlacebogroupinSHIFTtrial– RiskofCVdeathorHFhospitalizaIon• 2.9%per1BPMincrease• 15.6%per5BPMincrease
• HR<60bpmvs.>75bpm– 32.4%decreasemortality&HFhospitalizaIon
![Page 63: NEW DRUG UPDATE 2016 - cdn.ymaws.com · • New Drug Update 2016 is accredited for 1.5 contact hours – Pharmacists ACPE 0154-0000-16-010-L01-P – Technicians ACPE 0154-0000-16-010-L01-T](https://reader033.vdocument.in/reader033/viewer/2022060600/60543e4917da3737fa6a5a6a/html5/thumbnails/63.jpg)
HRRegulaIon• SAnodeproduces“pacemaker”impulses– SpreadstoAVnodetriggeringventricularcontracIon
• Ifcurrent– IniIatesdiastolicdepolarizaIonofSAnode
![Page 64: NEW DRUG UPDATE 2016 - cdn.ymaws.com · • New Drug Update 2016 is accredited for 1.5 contact hours – Pharmacists ACPE 0154-0000-16-010-L01-P – Technicians ACPE 0154-0000-16-010-L01-T](https://reader033.vdocument.in/reader033/viewer/2022060600/60543e4917da3737fa6a5a6a/html5/thumbnails/64.jpg)
Ivabradine• Ifinhibitor– BindstoHCNchannels
• “usedependent”
• SAnode(fchannels)– CarriesIfcurrent
• prolongsdiastolicIme• InhibiIonreducesheartrate
• ReIna(hchannels)– CarriesIhcurrent
• InhibiIoncausesvisualdisturbances
![Page 65: NEW DRUG UPDATE 2016 - cdn.ymaws.com · • New Drug Update 2016 is accredited for 1.5 contact hours – Pharmacists ACPE 0154-0000-16-010-L01-P – Technicians ACPE 0154-0000-16-010-L01-T](https://reader033.vdocument.in/reader033/viewer/2022060600/60543e4917da3737fa6a5a6a/html5/thumbnails/65.jpg)
Ivabradine• ProlongsdiastolicIme– InhibitsIfcurrent,reducingheartrate
• Increasesstrokevolume– PreservesmyocardialcontracIlity
– BP
NatRevDrugDisc2006;5:1034
![Page 66: NEW DRUG UPDATE 2016 - cdn.ymaws.com · • New Drug Update 2016 is accredited for 1.5 contact hours – Pharmacists ACPE 0154-0000-16-010-L01-P – Technicians ACPE 0154-0000-16-010-L01-T](https://reader033.vdocument.in/reader033/viewer/2022060600/60543e4917da3737fa6a5a6a/html5/thumbnails/66.jpg)
Ivabradine• HFrEFpaIents
– ElevatedHR• Increaseinmorbidity&mortality
• HR≥87BPM– >2XriskforCVdeathorhospitalizaIonforHFvs.HR70-72BPM• HazardraIo2.34,95%CI1.84–2.98,p<0.0001
• ElderlyHFpEFpaIentshadsymptomaIcimprovement&HRreducIon
EurHeartJ2013;34:suppl1CirculaIon2001;103:1428
Lancet2010;376:886
![Page 67: NEW DRUG UPDATE 2016 - cdn.ymaws.com · • New Drug Update 2016 is accredited for 1.5 contact hours – Pharmacists ACPE 0154-0000-16-010-L01-P – Technicians ACPE 0154-0000-16-010-L01-T](https://reader033.vdocument.in/reader033/viewer/2022060600/60543e4917da3737fa6a5a6a/html5/thumbnails/67.jpg)
Ivabradine(Corlanor®)• ApprovedtoreducehospitalizaIonfromHF– ConsiderinHFrEF
• LVEF≤35%• ResIngheartrate
– ≥70BPM
• OnmaxdoseofBB– Orintolerant
• TitratetoresIngHR